Neurovascular device maker Rapid Medical said it won CE Mark approval in the European Union for its Tigertriever 13 stent retriever intended for treating ischemic stroke, and added that the first patient in the region has been treated with the device.
The Israel-based company touted the Tigertriever 13 as the first-ever fully-visible stent retriever that can be adjusted by the physician to fit in the dimensions of the blocked blood vessel.
Rapid Medical said that the device’s profile is 83% smaller than any other devices on the market, and that it is designed to recanalyze intracranial vessels of between 1mm and 2.5mm.
“We know that endovascular therapy is the best option for large vessel occlusions. The Tigertrriever 13 will further extend this powerful treatment for acute ischemic stroke to patients with medium vessel occlusions,” Dr. Jeffrey Saver of UCLA’s David Geffen School of Medicine said in a prepared statement.
The company said it plans to launch the Tigertriever 13 in the EU during the third quarter of this year.
Last September, Rapid Medical said it launched a registry study of its Tigertreiver controllable stent retriever.